<DOC>
	<DOCNO>NCT00025441</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat child metastatic rhabdomyosarcoma malignant mesenchymal tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Metastatic Rhabdomyosarcoma Other Malignant Mesenchymal Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall survival child metastatic rhabdomyosarcoma malignant mesenchymal tumor treat one two different chemotherapy regimen base upon risk group . - Determine role low-intensity maintenance chemotherapy intensive conventional chemotherapy standard-risk child . - Determine value therapeutic window high-risk child . - Determine role sequential high-dose chemotherapy peripheral blood stem cell transplantation achieve complete response high-risk child . - Determine complete response , overall survival , event-free survival high-risk child . OUTLINE : This multicenter study . Patients stratify accord risk group ( standard vs high ) . Standard-risk patient : - Initial chemotherapy : Patients receive vincristine IV day 1 week 1-7 . Patients also receive dactinomycin IV day 1 ifosfamide IV 1 hour day 1-3 week 1 . Patients receive carboplatin IV 1 hour epirubicin IV 6 hour day 1 week 4 . Patients receive ifosfamide IV 1 hour etoposide IV 4 hour day 1-3 week 7 . Treatment repeat every 8 week 3 course absence disease progression unacceptable toxicity . After second course , patient le 50 % partial response ( PR ) remove study . Patients parameningeal disease undergo radiotherapy 5 day week 8 week begin week 9 . - Maintenance chemotherapy : Patients receive cyclophosphamide IV 1 hour , vincristine IV , dactinomycin IV day 1 . Treatment repeat every 3 week 9 course absence disease progression unacceptable toxicity . Patients remain PR week 17 undergo radiotherapy 9 week begin week 18 . High-risk patient : - Initial chemotherapy : Patients receive window study drug carboplatin IV 1 hour doxorubicin day 1 . Treatment repeat every 3 week 2 course . Patients receive high-dose cyclophosphamide IV 1 hour day 1-3 week 7 . Beginning day 8 , patient receive filgrastim ( G-CSF ) IV subcutaneously ( SC ) daily day 13 . Patients may undergo peripheral blood stem cell ( PBSC ) collection . Patients receive high-dose etoposide IV 24 hour day 15-17 . Beginning day 22 , patient receive G-CSF IV SC daily day 27 . Patients receive high-dose cyclophosphamide IV 1 hour day 29-31 . Beginning day 36 , patient receive G-CSF IV SC daily day 42 . Patients may undergo PBSC collection previously perform . Patients achieve complete response ( CR ) remove study . Patients receive high-dose carboplatin IV 1 hour day 44-48 . Patients undergo PBSC reinfusion day 52 . Beginning day 55 , patient receive G-CSF IV SC daily blood count recover . - Maintenance chemotherapy : Patients receive maintenance chemotherapy comprise cyclophosphamide , vincristine , dactinomycin manner standard-risk patient . Patients parameningeal disease achieve CR undergo radiotherapy begin week 17 . Patients achieve CR , unless metastatic disease resect , undergo radiotherapy begin week 15 . Patients follow every 2 month 2 year , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 8-30 standard-risk patient accrue study within 4 year . A total 15-75 high-risk patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic rhabdomyosarcoma malignant mesenchymal tumor Standard risk define : Less 10 year age No bone bone marrow involvement High risk define : At least 10 year age OR Bone bone marrow involvement Diagnosed less 8 week ago Previously untreated disease except initial surgery within past 8 week PATIENT CHARACTERISTICS : Age : 6 month 18 year Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : No prior endocrine therapy Radiotherapy : Concurrent radiotherapy allow Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>chondrosarcoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>fibrosarcomatous osteosarcoma</keyword>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>alveolar childhood rhabdomyosarcoma</keyword>
	<keyword>pleomorphic childhood rhabdomyosarcoma</keyword>
	<keyword>mixed childhood rhabdomyosarcoma</keyword>
	<keyword>embryonal-botryoid childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>childhood fibrosarcoma</keyword>
	<keyword>childhood synovial sarcoma</keyword>
	<keyword>childhood malignant hemangiopericytoma</keyword>
	<keyword>childhood liposarcoma</keyword>
	<keyword>childhood alveolar soft-part sarcoma</keyword>
	<keyword>childhood leiomyosarcoma</keyword>
	<keyword>childhood angiosarcoma</keyword>
	<keyword>childhood epithelioid sarcoma</keyword>
	<keyword>childhood malignant mesenchymoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>childhood desmoplastic small round cell tumor</keyword>
</DOC>